Key Highlights
- Expanded Accessibility: Leveraging Walgreens pharmacies to host clinical trials, enhancing access for diverse communities.
- Community-Centric Approach: Introduction of mobile research units by EmVenio to increase trial participation options.
- Impact on Public Health: Addressing critical health needs in obesity, overweight, and diabetes through innovative community engagement.
Source: Business Wire
Notable Quotes
- “Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” – Ramita Tandon, Chief Clinical Trials Officer at Walgreens
- “Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” – Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim
- “Our partnership with Boehringer Ingelheim exemplifies our commitment to breaking down barriers and expanding access to transformative healthcare solutions,” – Thad Wolfram, President at EmVenio Research
SoHC's Take
This strategic collaboration between Walgreens, Boehringer Ingelheim, and EmVenio Research marks a significant step forward in making clinical trials more accessible and equitable. By utilizing the widespread network of Walgreens pharmacies and the innovative mobile research units provided by EmVenio, this initiative promises to enhance patient outcomes and set new standards for inclusivity in clinical research. This community-based approach not only expands access to critical clinical trials but also fosters a more inclusive environment that reflects the diverse needs of the community, especially among underserved populations.
